196 related articles for article (PubMed ID: 29277894)
1. The sphingosine kinase 2 inhibitor ABC294640 displays anti-non-small cell lung cancer activities in vitro and in vivo.
Dai L; Smith CD; Foroozesh M; Miele L; Qin Z
Int J Cancer; 2018 May; 142(10):2153-2162. PubMed ID: 29277894
[TBL] [Abstract][Full Text] [Related]
2. ABC294640, a sphingosine kinase 2 inhibitor, enhances the antitumor effects of TRAIL in non-small cell lung cancer.
Yang J; Yang C; Zhang S; Mei Z; Shi M; Sun S; Shi L; Wang Z; Wang Y; Li Z; Xie C
Cancer Biol Ther; 2015; 16(8):1194-204. PubMed ID: 26054751
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of ceramide glucosylation sensitizes lung cancer cells to ABC294640, a first-in-class small molecule SphK2 inhibitor.
Guan S; Liu YY; Yan T; Zhou J
Biochem Biophys Res Commun; 2016 Aug; 476(4):230-236. PubMed ID: 27221045
[TBL] [Abstract][Full Text] [Related]
4. Sphingosine kinase-2 Inhibitor ABC294640 Enhances Doxorubicin-Induced Apoptosis of NSCLC Cells via Altering Survivin Expression.
Hasanifard L; Samadi N; Rashtchizadeh N; Dastmalchi S; Karimi P
Drug Res (Stuttg); 2018 Jan; 68(1):45-53. PubMed ID: 28950390
[TBL] [Abstract][Full Text] [Related]
5. Targeting sphingosine kinase 2 (SphK2) by ABC294640 inhibits colorectal cancer cell growth in vitro and in vivo.
Xun C; Chen MB; Qi L; Tie-Ning Z; Peng X; Ning L; Zhi-Xiao C; Li-Wei W
J Exp Clin Cancer Res; 2015 Sep; 34(1):94. PubMed ID: 26337959
[TBL] [Abstract][Full Text] [Related]
6. Targeting NFĸB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2.
Antoon JW; White MD; Slaughter EM; Driver JL; Khalili HS; Elliott S; Smith CD; Burow ME; Beckman BS
Cancer Biol Ther; 2011 Apr; 11(7):678-89. PubMed ID: 21307639
[TBL] [Abstract][Full Text] [Related]
7. Targeting sphingosine kinase 2 by ABC294640 inhibits human skin squamous cell carcinoma cell growth.
Zhou J; Chen J; Yu H
Biochem Biophys Res Commun; 2018 Mar; 497(2):535-542. PubMed ID: 29428730
[TBL] [Abstract][Full Text] [Related]
8. The Sphingosine Kinase 2 Inhibitor ABC294640 Reduces the Growth of Prostate Cancer Cells and Results in Accumulation of Dihydroceramides In Vitro and In Vivo.
Venant H; Rahmaniyan M; Jones EE; Lu P; Lilly MB; Garrett-Mayer E; Drake RR; Kraveka JM; Smith CD; Voelkel-Johnson C
Mol Cancer Ther; 2015 Dec; 14(12):2744-52. PubMed ID: 26494858
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells.
Ding X; Chaiteerakij R; Moser CD; Shaleh H; Boakye J; Chen G; Ndzengue A; Li Y; Zhou Y; Huang S; Sinicrope FA; Zou X; Thomas MB; Smith CD; Roberts LR
Oncotarget; 2016 Apr; 7(15):20080-92. PubMed ID: 26956050
[TBL] [Abstract][Full Text] [Related]
10. The Sphingosine Kinase 2 Inhibitor ABC294640 Restores the Sensitivity of BRAFV600E Mutant Colon Cancer Cells to Vemurafenib by Reducing AKT-Mediated Expression of Nucleophosmin and Translationally-Controlled Tumour Protein.
Grbčić P; Eichmann TO; Kraljević Pavelić S; Sedić M
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639107
[TBL] [Abstract][Full Text] [Related]
11. Targeting sphingosine kinase 1/2 by a novel dual inhibitor SKI-349 suppresses non-small cell lung cancer cell growth.
Xue Y; Jiang K; Ou L; Shen M; Yang Y; Lu J; Xu W
Cell Death Dis; 2022 Jul; 13(7):602. PubMed ID: 35831279
[TBL] [Abstract][Full Text] [Related]
12. ABC294640, A Novel Sphingosine Kinase 2 Inhibitor, Induces Oncogenic Virus-Infected Cell Autophagic Death and Represses Tumor Growth.
Dai L; Bai A; Smith CD; Rodriguez PC; Yu F; Qin Z
Mol Cancer Ther; 2017 Dec; 16(12):2724-2734. PubMed ID: 28939554
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts.
Beljanski V; Lewis CS; Smith CD
Cancer Biol Ther; 2011 Mar; 11(5):524-34. PubMed ID: 21258214
[TBL] [Abstract][Full Text] [Related]
14. Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2.
French KJ; Zhuang Y; Maines LW; Gao P; Wang W; Beljanski V; Upson JJ; Green CL; Keller SN; Smith CD
J Pharmacol Exp Ther; 2010 Apr; 333(1):129-39. PubMed ID: 20061445
[TBL] [Abstract][Full Text] [Related]
15. Ceramides promote apoptosis for virus-infected lymphoma cells through induction of ceramide synthases and viral lytic gene expression.
Dai L; Trillo-Tinoco J; Bai A; Chen Y; Bielawski J; Del Valle L; Smith CD; Ochoa AC; Qin Z; Parsons C
Oncotarget; 2015 Sep; 6(27):24246-60. PubMed ID: 26327294
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma.
Venkata JK; An N; Stuart R; Costa LJ; Cai H; Coker W; Song JH; Gibbs K; Matson T; Garrett-Mayer E; Wan Z; Ogretmen B; Smith C; Kang Y
Blood; 2014 Sep; 124(12):1915-25. PubMed ID: 25122609
[TBL] [Abstract][Full Text] [Related]
17. Proteasomal degradation of sphingosine kinase 1 and inhibition of dihydroceramide desaturase by the sphingosine kinase inhibitors, SKi or ABC294640, induces growth arrest in androgen-independent LNCaP-AI prostate cancer cells.
McNaughton M; Pitman M; Pitson SM; Pyne NJ; Pyne S
Oncotarget; 2016 Mar; 7(13):16663-75. PubMed ID: 26934645
[TBL] [Abstract][Full Text] [Related]
18. Developing new ceramide analogs against non-small cell lung cancer (NSCLC).
Dai L; Goyal N; Liu J; Foroozesh M; Qin Z
Am J Cancer Res; 2024; 14(1):86-96. PubMed ID: 38323290
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of Sphk2 is associated with gefitinib resistance in non-small cell lung cancer.
Liu W; Ning J; Li C; Hu J; Meng Q; Lu H; Cai L
Tumour Biol; 2016 May; 37(5):6331-6. PubMed ID: 26628299
[TBL] [Abstract][Full Text] [Related]
20. A novel sphingosine kinase inhibitor induces autophagy in tumor cells.
Beljanski V; Knaak C; Smith CD
J Pharmacol Exp Ther; 2010 May; 333(2):454-64. PubMed ID: 20179157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
